公开(公告)号：US20110003759A1

公开(公告)日：2011-01-06

申请号：US12881234

申请日：2010-09-14

申请人： Philip D. Stein ,  Sharon N. Bisaha ,  Saleen Ahmad ,  Khehyong Ngu ,  William N. Washburn

发明人： Philip D. Stein ,  Sharon N. Bisaha ,  Saleen Ahmad ,  Khehyong Ngu ,  William N. Washburn

IPC分类号： A61K31/497 ,  C07D241/18 ,  C07D401/12 ,  C07D403/12 ,  A61K31/4965 ,  A61K31/7034 ,  A61K31/5513 ,  A61P3/10 ,  A61P25/24 ,  A61P25/22 ,  A61P25/30 ,  A61P25/16 ,  A61P25/18 ,  A61P19/02 ,  A61P17/00

CPC分类号： C07D241/18 ,  C07D401/12

摘要： The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein R1, R2, R3, R8, and R9 are defined herein.Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.

摘要翻译： 本申请提供化合物，包括其中R 1，R 2，R 3，R 8和R 9在本文中定义的根据式I的所有立体异构体，溶剂合物，前药和药学上可接受的形式。 另外，本申请提供含有至少一种根据式I的化合物和任选的至少一种另外的治疗剂的药物组合物。 最后，本申请提供了通过施用治疗有效剂量的根据式I的化合物治疗患有MCHR-1调节的疾病或病症例如肥胖，糖尿病，抑郁或焦虑的患者的方法。

公开(公告)号：US20090011994A1

公开(公告)日：2009-01-08

申请号：US12141228

申请日：2008-06-18

申请人： Philip D. Stein ,  Sharon N. Bisaha ,  Saleen Ahmad ,  Khehyong Ngu ,  William N. Washburn

发明人： Philip D. Stein ,  Sharon N. Bisaha ,  Saleen Ahmad ,  Khehyong Ngu ,  William N. Washburn

IPC分类号： A61K38/22 ,  A61K31/4965 ,  C07D241/18 ,  A61K31/497 ,  A61P3/04 ,  A61P3/10 ,  A61K31/60 ,  C07D401/04 ,  A61K31/675

CPC分类号： C07D241/18 ,  C07D401/12

摘要： The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein R1, R2, R3, R8, and R9 are defined herein.Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.

摘要翻译： 本申请提供化合物，包括其中R 1，R 2，R 3，R 8和R 9在本文中定义的根据式I的所有立体异构体，溶剂合物，前药和药学上可接受的形式。 另外，本申请提供含有至少一种根据式I的化合物和任选的至少一种另外的治疗剂的药物组合物。 最后，本申请提供了通过施用治疗有效剂量的根据式I的化合物治疗患有MCHR-1调节的疾病或病症例如肥胖，糖尿病，抑郁或焦虑的患者的方法。